FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2338987112> ?p ?o ?g. }

• W2338987112 endingPage "30" @default.
• W2338987112 startingPage "22" @default.
• W2338987112 abstract "The serology of patients with Rheumatoid arthritis (RA) is characterized by persistently raised levels of autoantibodies: Rheumatoid Factors (RhF) against Fc of IgG, and to citrullinated (Cit) protein/peptide sequences: ACPA, recognizing multiple Cit-sequences. B cell depletion therapy based on rituximab delivers good clinical responses in RA patients, particularly in the seropositive group, with responses sometimes lasting beyond the phase of B cell reconstitution. In general, ACPA levels fall following rituximab, but fluctuations with respect to predicting relapse have proved disappointing. In order to identify possible immunodominant specificities within either IgG- or IgA-ACPA we used a Multiplex bead-based array consisting of 30 Cit-peptides/proteins and 22 corresponding native sequences. The kinetics of the serum ACPA response to individual specificities was measured at key points (Baseline, B cell depletion phase, Relapse) within an initial cycle of rituximab therapy in 16 consecutive patients with severe, active RA. All had achieved significant decreases in Disease Activity Scores-28 and maintained B cell depletion in the peripheral blood (<5 CD19+cells/μl) for at least 3 months. At Baseline, mean fluorescence intensity shown by individual IgG- and IgA-ACPA were strongly correlated (R2 = 0.75; p < 0.0001) but IgA-ACPA were approximately 10-fold lower. Data were Z-normalised in order to compare serial results and antibody classes. At Baseline, a total of 68 IgG- and 51 IgA-ACPA had Z-scores ≥ 1 (above population mean) were identified, with at least one Cit-antigen identified in each serum. ACPA to individual specificities subsequently fluctuated with 3 different patterns. Most 51/68 (75%) IgG- and 48/51 IgA-ACPA (94%) fell between Baseline and Depletion, of which 57% IgG- and 65% IgA-ACPA rebounded pre-Relapse. Interestingly, 17/68 IgG-ACPA (25%) and some IgA-ACPA (3/51; 6%) transiently increased from Baseline, subsequently falling pre-Relapse. Individual responses to particular Cit-epitopes were not linked to particular patterns of fluctuation, but IgG- and IgA-ACPA to individual Cit-antigens often followed similar courses. Some new IgG- and IgA-ACPA, generally to different Cit-antigens however, arose at Relapse in 4 patients. The complexities of the ACPA response after rituximab may therefore reflect its ability to deplete or modify the function of parent B cell clones, which varies between patients. Although relapse following rituximab invariably follows naïve B cell exit from the bone marrow, these studies show that interactions between both ‘new’ and residual autoreactive memory B cells may be key to resumption of symptoms. The lack of identification of any immunodominant specificity suggests that the process of citrullination, rather than any particular Cit-antigen drives the autoimmune response in RA patients." @default.
• W2338987112 created "2016-06-24" @default.
• W2338987112 creator A5012284370 @default.
• W2338987112 creator A5014721829 @default.
• W2338987112 creator A5017952944 @default.
• W2338987112 creator A5046429545 @default.
• W2338987112 creator A5072708850 @default.
• W2338987112 creator A5082185560 @default.
• W2338987112 date "2016-06-01" @default.
• W2338987112 modified "2023-10-02" @default.
• W2338987112 title "B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens" @default.
• W2338987112 cites W1581336840 @default.
• W2338987112 cites W1713693487 @default.
• W2338987112 cites W1772093119 @default.
• W2338987112 cites W1971388666 @default.
• W2338987112 cites W1978827806 @default.
• W2338987112 cites W1982703352 @default.
• W2338987112 cites W1985380203 @default.
• W2338987112 cites W1998618256 @default.
• W2338987112 cites W1998890104 @default.
• W2338987112 cites W2008861688 @default.
• W2338987112 cites W2009900263 @default.
• W2338987112 cites W2020734970 @default.
• W2338987112 cites W2024988150 @default.
• W2338987112 cites W2031294882 @default.
• W2338987112 cites W2038140273 @default.
• W2338987112 cites W2040884296 @default.
• W2338987112 cites W2052233370 @default.
• W2338987112 cites W2067199567 @default.
• W2338987112 cites W2070143969 @default.
• W2338987112 cites W2071562052 @default.
• W2338987112 cites W2085192554 @default.
• W2338987112 cites W2096966555 @default.
• W2338987112 cites W2104669609 @default.
• W2338987112 cites W2109078821 @default.
• W2338987112 cites W2111608476 @default.
• W2338987112 cites W2114942161 @default.
• W2338987112 cites W2115694552 @default.
• W2338987112 cites W2118994799 @default.
• W2338987112 cites W2121875491 @default.
• W2338987112 cites W2122507029 @default.
• W2338987112 cites W2128384929 @default.
• W2338987112 cites W2129961994 @default.
• W2338987112 cites W2131131455 @default.
• W2338987112 cites W2132841358 @default.
• W2338987112 cites W2133397275 @default.
• W2338987112 cites W2139209979 @default.
• W2338987112 cites W2149055576 @default.
• W2338987112 cites W2152451684 @default.
• W2338987112 cites W2158434979 @default.
• W2338987112 cites W2160466593 @default.
• W2338987112 cites W2163652380 @default.
• W2338987112 cites W2170924625 @default.
• W2338987112 cites W2269217719 @default.
• W2338987112 doi "https://doi.org/10.1016/j.jaut.2016.03.010" @default.
• W2338987112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27055777" @default.
• W2338987112 hasPublicationYear "2016" @default.
• W2338987112 type Work @default.
• W2338987112 sameAs 2338987112 @default.
• W2338987112 citedByCount "23" @default.
• W2338987112 countsByYear W23389871122016 @default.
• W2338987112 countsByYear W23389871122017 @default.
• W2338987112 countsByYear W23389871122018 @default.
• W2338987112 countsByYear W23389871122019 @default.
• W2338987112 countsByYear W23389871122020 @default.
• W2338987112 countsByYear W23389871122021 @default.
• W2338987112 countsByYear W23389871122022 @default.
• W2338987112 countsByYear W23389871122023 @default.
• W2338987112 crossrefType "journal-article" @default.
• W2338987112 hasAuthorship W2338987112A5012284370 @default.
• W2338987112 hasAuthorship W2338987112A5014721829 @default.
• W2338987112 hasAuthorship W2338987112A5017952944 @default.
• W2338987112 hasAuthorship W2338987112A5046429545 @default.
• W2338987112 hasAuthorship W2338987112A5072708850 @default.
• W2338987112 hasAuthorship W2338987112A5082185560 @default.
• W2338987112 hasConcept C147483822 @default.
• W2338987112 hasConcept C159654299 @default.
• W2338987112 hasConcept C163764329 @default.
• W2338987112 hasConcept C203014093 @default.
• W2338987112 hasConcept C2777575956 @default.
• W2338987112 hasConcept C2778453870 @default.
• W2338987112 hasConcept C2778957590 @default.
• W2338987112 hasConcept C2780653079 @default.
• W2338987112 hasConcept C2781188995 @default.
• W2338987112 hasConcept C2908647359 @default.
• W2338987112 hasConcept C45189115 @default.
• W2338987112 hasConcept C60644358 @default.
• W2338987112 hasConcept C71924100 @default.
• W2338987112 hasConcept C86803240 @default.
• W2338987112 hasConcept C99454951 @default.
• W2338987112 hasConceptScore W2338987112C147483822 @default.
• W2338987112 hasConceptScore W2338987112C159654299 @default.
• W2338987112 hasConceptScore W2338987112C163764329 @default.
• W2338987112 hasConceptScore W2338987112C203014093 @default.
• W2338987112 hasConceptScore W2338987112C2777575956 @default.
• W2338987112 hasConceptScore W2338987112C2778453870 @default.
• W2338987112 hasConceptScore W2338987112C2778957590 @default.
• W2338987112 hasConceptScore W2338987112C2780653079 @default.

• next